ProCE Banner Activity

Maintenance Strategies for AML Today: Experts Answer Frequently Asked Questions

Clinical Thought

In this commentary, experts answer questions about maintenance strategies after chemotherapy or transplant in patients with acute myeloid leukemia asked by the audience during a live webinar in June 2023.

Released: July 27, 2023

Share

Faculty

Amir T. Fathi

Amir T. Fathi, MD

Director, Leukemia Program
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Eytan M. Stein

Eytan M. Stein, MD

Chief, Leukemia Service
Director, Program for Drug Development in Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Amer Zeidan

Amer Zeidan, MBBS, MHS

Associate Professor of Medicine (Hematology)
Chief, Division of Hematologic Malignancies
Yale Comprehensive Cancer Center and Smilow Cancer Hospital
New Haven, Connecticut

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb

Program Director Disclosure

Program Director

Eytan M. Stein, MD

Chief, Leukemia Service
Director, Program for Drug Development in Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Eytan Stein, MD: consultant/advisor/speaker: AbbVie, Agios, Aptose, Astellas, Blueprint, Bristol Myers Squibb, Calithera, CTI Biopharma, Daiichi Sankyo, Foghorn, Genentech, Genesis, Gilead, Janssen, Jazz Pharmaceuticals, Kura, Menarini, Neoleukin, Novartis, OnCusp, Ono Pharma, PinotBio, Servier, Syndax, Syros; data and safety monitoring board: Cellectis, Epizyme; researcher: Bristol Myers Squibb, Eisai; stock/stock options: Auron.

Faculty Disclosure

Primary Author

Amir T. Fathi, MD

Director, Leukemia Program
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Amir Fathi, MD: consultant/advisor/speaker: AbbVie, Agios, Amgen, Astellas, Autolus, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, Enclear, Forma, Genentech, Immunogen, Ipsen, Kite, Mablytics, Menarini, Novartis, Orum, Pfizer, PureTech, Remix, Rigel, Servier, Takeda; owner: AbbVie, Bristol-Myers Squibb, Servier.

Amer Zeidan, MBBS, MHS

Associate Professor of Medicine (Hematology)
Chief, Division of Hematologic Malignancies
Yale Comprehensive Cancer Center and Smilow Cancer Hospital
New Haven, Connecticut

Amer Zeidan, MBBS: researcher: AbbVie, ADC Therapeutics, Amgen, Aprea, Astex, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Cardiff Oncology, Celgene, Geron, Incyte, Medimmune, Novartis, Otsuka, Pfizer, Shattuck Labs, Takeda, Trovagene; consultant: AbbVie, Acceleron, Agios, ALX Oncology, Amgen, Aprea, Astellas, BeyondSpring, Biocryst, Boehringer Ingelheim, Bristol-Myers Squibb, Cardiff Oncology, Cardinal Health, Celgene, Chiesi, Daiichi Sankyo, Epizyme, Foran, Genentech, Geron, Gilead, Incyte, Ionis, Janssen, Jazz, Kura, Mendus, Notable, Novartis, Orum, Otsuka, Pfizer, Seattle Genetics, Servier, Syndax, Syros, Taiho, Takeda, Trovagene, Tyme.